Tiemann Investment Advisors LLC Acquires 302 Shares of Pfizer Inc. (NYSE:PFE)

Tiemann Investment Advisors LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,980 shares of the biopharmaceutical company’s stock after buying an additional 302 shares during the quarter. Tiemann Investment Advisors LLC’s holdings in Pfizer were worth $649,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Heritage Way Advisors LLC boosted its holdings in shares of Pfizer by 0.6% in the second quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock valued at $2,492,000 after purchasing an additional 354 shares during the period. Natixis purchased a new stake in shares of Pfizer in the second quarter valued at approximately $258,466,000. Machina Capital S.A.S. lifted its holdings in Pfizer by 14.4% during the second quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock worth $1,899,000 after buying an additional 5,522 shares during the period. M Holdings Securities Inc. lifted its holdings in Pfizer by 27.9% during the first quarter. M Holdings Securities Inc. now owns 39,851 shares of the biopharmaceutical company’s stock worth $1,692,000 after buying an additional 8,693 shares during the period. Finally, Annex Advisory Services LLC lifted its holdings in Pfizer by 0.7% during the second quarter. Annex Advisory Services LLC now owns 51,785 shares of the biopharmaceutical company’s stock worth $2,243,000 after buying an additional 382 shares during the period. 71.84% of the stock is currently owned by hedge funds and other institutional investors.

Shares of PFE stock traded down $0.44 during trading hours on Friday, reaching $36.84. 14,539,309 shares of the company’s stock were exchanged, compared to its average volume of 21,779,912. The stock’s 50 day moving average is $36.81 and its 200-day moving average is $40.81. The company has a market cap of $207.47 billion, a price-to-earnings ratio of 12.28, a P/E/G ratio of 2.97 and a beta of 0.65. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $46.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.05. The business had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business’s quarterly revenue was down 1.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.77 earnings per share. Equities analysts anticipate that Pfizer Inc. will post 2.81 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd were given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.91%. The ex-dividend date of this dividend was Thursday, August 1st. Pfizer’s payout ratio is presently 48.00%.

In other news, Director Scott Gottlieb bought 3,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $104,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the completion of the transaction, the insider now directly owns 80,094 shares in the company, valued at $3,524,136. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

A number of analysts have weighed in on the company. DZ Bank upgraded Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price for the company in a report on Wednesday, August 28th. Goldman Sachs Group restated a “buy” rating and set a $49.00 target price on shares of Pfizer in a report on Monday, June 17th. UBS Group restated a “neutral” rating and set a $43.00 target price on shares of Pfizer in a report on Monday, August 5th. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. Fifteen investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Pfizer has an average rating of “Hold” and an average target price of $45.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: Diluted Earnings Per Share

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.